Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 5/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5478973 | 0.91 | KCNH2 (0.38) | BACE1KCNH2MCHR1KAT2BACKR3 | |
| SCHEMBL593222 | 0.90 | JAK2 (0.34) | BACE1KCNH2MCHR1KAT2BACKR3 | |
| SCHEMBL592322 | 0.88 | PRKAA2 (0.35) | BACE1KCNH2MCHR1KAT2BACKR3 | |
| SCHEMBL594333 | 0.88 | FAAH (0.35) | BACE1KCNH2MCHR1KAT2BFAAH | |
| SCHEMBL593414 | 0.88 | POLB (0.34) | BACE1KCNH2MCHR1KAT2BACKR3 | |
| SCHEMBL593704 | 0.87 | ALDH1A1 (0.39) | BACE1KCNH2FAAH | |
| SCHEMBL8268428 | 0.87 | ROCK2 (0.34) | BACE1KCNH2MCHR1KAT2BACKR3 | |
| SCHEMBL594013 | 0.87 | FAAH (0.39) | BACE1KCNH2MCHR1KAT2BACKR3 | |
| SCHEMBL593626 | 0.87 | KAT2B (0.38) | BACE1KCNH2MCHR1KAT2BBACE2 | |
| SCHEMBL13031027 | 0.87 | ACKR3 (0.39) | BACE1KCNH2MCHR1KAT2BACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114887-B2 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | BACE1, BACE2, APP | BACE1 1/4885KCNH2 1880/4885MCHR1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.